Supplementary Protocol S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma

Paolo Strati; Lei Feng; Andrey Tyshevich; Darya Shavronskaya; Julia Alesse; Noel English; E. Sheehan; Nikita Syzrantsev; Alexander Nesmelov; Tony Zhuang; Dai Chihara; Jason R. Westin; Sairah Ahmed; Luis Fayad; Jared Henderson; Karin M. Dent; Elizabeth McChesney; Sattva S. Neelapu; Christopher R. Flowers

doi:10.1158/1078-0432.30255107

Key Points

The trial explores the combination therapy's safety and tolerability in patients with B-cell non-Hodgkin lymphoma, indicating a potential new treatment approach.
Key findings include the definition of dose-limiting toxicity (DLT) which helps manage treatment risks, ensuring patient safety during the trial process.
Eligibility criteria are established to select appropriate participants, helping to optimize the efficacy of evorpacept with lenalidomide and rituximab.
This phase I trial represents a critical step in evaluating new therapeutic strategies for B-cell non-Hodgkin lymphoma, paving the way for future research.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Phase I trial investigates the safety of evorpacept with lenalidomide and rituximab in patients, aiming to establish eligibility criteria and monitor dosage limits.

Abstract

Eligibility criteria and DLT definition

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Strati et al. (2025) studied this question.

synapsesocial.com/papers/68de68f683cbc991d0a21cda https://doi.org/10.1158/1078-0432.30255107

View Full Paper

Ask AI

Bookmark

Share

Supplementary Protocol S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Protocol S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading